Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Evolus, Inc. - Common Stock
(NQ:
EOLS
)
5.350
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Evolus, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Evolus Earnings Preview
↗
May 08, 2023
Via
Benzinga
Evolus to Report First Quarter 2023 Results and Provide Business Update
May 05, 2023
From
Evolus, Inc.
Via
Business Wire
Analyst Expectations for Evolus's Future
↗
March 09, 2023
Via
Benzinga
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
March 08, 2023
From
Evolus
Via
Business Wire
Evolus to Participate in the Barclays Global Healthcare Conference
February 28, 2023
From
Evolus
Via
Business Wire
Evolus Says 'Extra Strength' Jeuveau Shows A Durable Effect In Frown Lines
↗
January 30, 2023
Via
Benzinga
Why Evolus Shares Jumped This Week
↗
January 20, 2023
The company said it expects to turn a profit in the fourth quarter.
Via
The Motley Fool
Earnings Scheduled For March 8, 2023
↗
March 08, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.
Via
Benzinga
Preview: Evolus's Earnings
↗
March 07, 2023
Via
Benzinga
Evolus Initiates Nuceiva® Launch in Germany and Austria
February 27, 2023
From
Evolus, Inc.
Via
Business Wire
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
February 22, 2023
From
Evolus
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
February 20, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
February 17, 2023
Via
Benzinga
Evolus Not Affected by Recent Korean Court Ruling
February 10, 2023
From
Evolus
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
February 10, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
February 07, 2023
Via
Benzinga
Evolus to Participate in the SVB Securities Global Biopharma Conference
January 31, 2023
From
Evolus
Via
Business Wire
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
January 28, 2023
From
Evolus
Via
Business Wire
Evolus Receives Regulatory Approval for Nuceiva® in Australia
January 23, 2023
From
Evolus
Via
Business Wire
Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress
January 23, 2023
From
Evolus
Via
Business Wire
Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook
↗
January 19, 2023
Evolus Inc (NASDAQ: EOLS) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively.
Via
Benzinga
Why Evolus Shares Are Trading Higher Today
↗
January 18, 2023
Evolus, Inc. (NASDAQ: EOLS) shares are trading higher after the company issued fourth-quarter and full-year 2022 and announced full-year 2023 revenue guidance.
Via
Benzinga
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
January 18, 2023
Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+...
Via
Benzinga
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration
January 18, 2023
From
Evolus
Via
Business Wire
Evolus Extends Term of Credit Facility with Pharmakon Advisors
December 08, 2022
From
Evolus
Via
Business Wire
Evolus Reports Third Quarter 2022 Results and Provides Business Update
November 08, 2022
From
Evolus
Via
Business Wire
Evolus to Participate in November Conferences
November 02, 2022
From
Evolus
Via
Business Wire
Evolus to Report Third Quarter 2022 Results and Provide Business Update
October 25, 2022
From
Evolus
Via
Business Wire
Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain
October 04, 2022
From
Evolus
Via
Business Wire
Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022
September 21, 2022
From
Evolus
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
